^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ACBI1

    i
    Other names: ACBI1, ACBI-1, ACBI 1
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    SMARCA2 inhibitor, SMARCA4 inhibitor, PBRM1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] A mutation characteristics analysis of SMARCA4defSMARCA2wt in lung cancer (ESMO 2021)
    Selective SMARCA2 degrading agents (such as ACBI1, one of PROTAC drugs) can induce the death of SMARCA4-deficient cancer cells... Our analysis indicate the medication-related mutation characteristics of SMARCA4defSMARCA2wt in lung cancer, and may contribute to medication guidance.
    PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • TMB-H • PD-L1 overexpression • KRAS G12C • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • MET mutation • KRAS G12 • SMARCA4 mutation
    |
    Onco PanScan™
    |
    ACBI1